FILING ANALYSIS · MONDAY, NOVEMBER 16

ALX ONCOLOGY HOLDINGS INC ALXO — 8-K: Results of Operations and Financial Condition

neutral

The company reported Q3 financial results with cash and equivalents of $147.2 million, which is expected to fund operations through the first half of 2028, and announced expectations for topline data from clinical trials, including the ASPEN-09-Breast trial in 2H 2027 and ALX2004 Phase 1 trial data in December 2026.

The filing

8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+